2023年12月12日 · This is a randomized, open-label, multicenter study evaluating subjects with newly diagnosed multiple myeloma who are deemed eligible for high-dose therapy.

Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies. The HARMONY Alliance is a Public-Private Partnership for Big Data in Hematology including over 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies.

Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia trial)

In total, 1,503 adult patients ≤65 years old with symptomatic NDMM were enrolled across 172 European Myeloma Network (EMN) centers. Overall, 1,212 patients were randomized to either VMP (n = 495) or auto-HSCT after high-dose melphalan (n = 702) in R1.

2024年12月18日 · MajesTEC-4 (EMN30; MMY3003) is an open-label, randomized, multicenter, phase 3 study assessing the efficacy and safety of TECVAYLI in combination with lenalidomide (Tec-Len) and TECVAYLI alone vs lenalidomide alone as maintenance therapy after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). 1-3

2021年12月4日 · This is a retrospective, observational, multicenter study to collect Real-World Evidence (RWE) data on systemic AL-AMY patients in Europe. Data from paper/electronic medical records and/or electronic databases from key reference centers in Europe will be used.

2018年12月15日 · Official Title: A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy

2021年9月15日 · Background: Combined therapy with carfilzomib, bendamustine, and dexamethasone was evaluated in this multicenter phase 1/2 trial conducted within the European Myeloma Network (EMN09 trial). Methods: Sixty-three patients with relapsed/refractory multiple myeloma who had received ≥2 lines of prior therapy were included.

2022年5月25日 · ROTTERDAM, Netherlands and NEWTON, Mass., May 25, 2022 /PRNewswire/ -- The European Myeloma Network (EMN), an international collaborative network of expertise centers for multiple myeloma in...

2022年5月25日 · EMN has organized more than 30 international prospective trials in multiple myeloma and related diseases in collaboration with international pharmaceutical companies. EMN strongly supports translational research in its trials, focusing on modes of action of the drugs under investigation.